Innocan Pharma's CBD Treatments Progress Into The Next Stage

The State of Israel has become known globally as a technological powerhouse, whether in the fields of agriculture, medicine, cybertechnology or finance – now, a new treatment containing cannabidiol (CBD) could be the Jewish state’s next major technological breakthrough.

Innocan Pharma Corporation INNPFINNOIP) is a Canadian- Israeli focusing on the development of pharmaceuticals which utilize cannabidiol (CBD) with other chemical elements in order to create medical solutions and bring these products into the treatment market.

Innocan is generally dealing in the development of multiple drug delivery programs which encompass CBD. Their partnership with Ramot at Tel Aviv University has produced cutting edge technology which uses CBD to penetrate the central nervous system (CNS) and potentially the Coronavirus (COVID-19).

This week, Innocan announced that they will move onto the second stage of their new study after successfully testing CBD therapeutic effects on small and large animals through loaded liposome platform technology (LPT) in applicable diseases. The study will be administered at the Hebrew University of Jerusalem in Israel.

The study consisted of injecting mice and later rats with CBD and LPT so that researchers can analyze the effects of CBD in the blood stream and muscle tissue after 21 days. The animals were tested humanly and showed greater results through injection of CBD than through oral or smoking administration, where CBD only remained in the bloodstream for up to 36 hours.

These successful results are expected to lead the way for future experiments further testing the initial conclusions, which also indicated that orchestrating these injections once or twice a month may be a solution to alleviating pain and other prodromes.

The initial experiment, led by Dr. Ahuva Cern, Senior Researcher in Professor Chezy Barenholz’s lab at the Hebrew University of Jerusalem, resulted in notable gains. Professor Barenholtz, head of the Membrane and Liposome Department at the Hebrew University, is known for his leadership in initiating over 55 patent families, including the first FDA approved nano-drug for cancer treatment - Doxil.

"I believe that these additional animal and efficacy studies are extremely important and may result in a major milestone,” said Professor Barenholtz. “This may open a wide range of clinical applications, while maintaining the CBD level in the blood for a long period of time which may lead to better patient compliance. If successful, the technology may be beneficial for various indications.”

In light of these achievements, Innocan Israel, a full subsidiary of Innocan, has entered into an agreement to conduct worldwide exclusive research and licensing agreement with Yissum Research and Development Company, the commercial arm of the Hebrew University of Jerusalem.

Josh Horowitz is a VC investor with vast experiences in the fields of biotech and cannabis-related ventures